Rebates Provided to Hospitals and Clinics in the Seoul Metropolitan Area from 2010 to 2019
Fair Trade Commission Issues Corrective Order... Surcharge Waived in Consideration of Rehabilitation

The Fair Trade Commission has uncovered so-called "irregular rebate" practices, in which a pharmaceutical company tried to evade the law by using Contract Sales Organizations (CSOs) instead of providing rebates directly.

Dongseong Jeyak logo. Dongseong Jeyak homepage.

Dongseong Jeyak logo. Dongseong Jeyak homepage.

View original image

On the 18th, the Fair Trade Commission announced that it had issued a stern warning and corrective order to Dongsung Pharmaceutical Co., Ltd. for providing large amounts of cash to hospitals and clinics in return for prescribing its drugs. The investigation found that, from October 2010 to April 2019, Dongsung Pharmaceutical provided approximately 250 million won in cash to four hospitals and clinics in the Seoul metropolitan area for the purpose of getting its drugs adopted and increasing prescriptions.


The method became more sophisticated over time. In the early years (2010 to 2014), the company checked monthly prescription performance through sales staff of its affiliate Dongsung Biopharm, then purchased gift certificates in proportion to that performance, handed them to the sales staff, and had them converted into cash that was then distributed to hospitals.


However, as authorities tightened their monitoring of rebates, around July 2014 Dongsung Pharmaceutical switched to fully outsourcing its prescription drug sales to CSOs. In this process, the company persuaded existing affiliate sales staff to establish their own sales agencies, then paid them high commissions that included rebate costs, thereby providing money and valuables indirectly.


The Fair Trade Commission defined these practices as "unfair customer inducement," which distorts fair competition in the market by causing drugs to be selected based on the amount of undue benefits provided, rather than on price or quality. The commission particularly determined that the rebates provided by pharmaceutical companies ultimately become reflected in drug price calculations, making this a representative illegal practice that shifts economic harm onto patients as consumers.


The Fair Trade Commission decided to impose a corrective order on Dongsung Pharmaceutical, prohibiting the company from engaging in the same conduct in the future. However, in consideration of the fact that Dongsung Pharmaceutical is currently undergoing rehabilitation procedures in court, the commission exempted the company from a surcharge.



The Fair Trade Commission stated, "To establish a fair competitive order in the pharmaceutical market based on quality and price, we will continue to monitor rebate practices," adding, "In cooperation with related agencies such as the Ministry of Food and Drug Safety and the Ministry of Health and Welfare, we will further strengthen monitoring of unfair trade practices."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing